FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136132014> ?p ?o ?g. }

• W3136132014 endingPage "466" @default.
• W3136132014 startingPage "466" @default.
• W3136132014 abstract "Abstract Background - According to recommendations, AML patients with intermediate- or adverse-risk genetics are candidates for allogeneic SCT in first complete remission (CR1). In practice, only a minority of them undergoes SCT because of older age, comorbidities, poor tolerance of prior therapy, inability to achieve CR, or early relapse. The benefit associated with RIC-SCT is particularly difficult to assess in older patients, due to lower SCT numbers and strong selection biases. Patients & Methods - Between 2012 and 2016, 509 patients aged ≥60 years (median, 68 years [60-85]) were enrolled in the prospective older AML ALFA-1200 trial. Eighty-eight patients (17%) had secondary or therapy-related AML. ECOG performance status was 0/1/2/3/NA in 219/219/57/9/5 patients and comorbidity index (HCT-CI) was 0/1/2/3/4+/NA in 226/92/66/61/54/10 patients, respectively. Risk subgroup distribution was 76 favorable (15%), 347 intermediate (68%), and 86 adverse (17%), according to the ELN-2010 classification retaining double mutations only as favorable CEBPA mutations. Chemotherapy consisted of cytarabine (200 mg/m2/d CIV on day 1-7) and idarubicin (12 mg/m2/d on day 1-3) followed by 2 courses with intermediate-dose cytarabine at 1500 mg/m2/12h on days 1/3/5, reduced to 1000 mg/m2/dose in patients aged ≥70 years. Patients with intermediate- or adverse-risk AML and/or those who needed two courses to reach CR were eligible for allogeneic SCT in CR1 if a suitable donor (HLA-identical [id] sibling or 9-10/10 matched unrelated donor) and no acquired contra-indication. Overall Results - During first induction, 43 patients died before response evaluation, while 335 patients reached CR. Among the 131 patients with resistant AML, 71 received a second intensive course and 34 achieved CR (overall CR rate, 72.5%). The 60- and 100-day mortality rates were 9.4 and 13.0%, respectively. With a median follow-up of 26 months, 201/369 CR patients relapsed and 164 died, including 30 deaths in CR1. Median overall survival (OS) was 20.7 months (95% CI, 17.5-24.8) and OS was 46.8% (95% CI, 41.9-51.4) at 2 years. Median OS was 49.7, 22.5 and 9.4 months in the favorable, intermediate and adverse ELN-risk subgroup, respectively. Role of SCT - Among the 305 CR patients eligible for SCT, 93 proceeded to SCT in CR1. In addition, 22 patients with primary refractory AML and 25 patients relapsing prior to SCT eventually received SCT. Patients transplanted in CR1 were younger (median age, 64 [60-73] vs 70 [60-81] years; p Conclusion - In older AML patients, due to persistent high TRM and relapse incidence, RIC-SCT significantly prolongs survival in the adverse ELN-risk AML subset only. Even if a longer follow-up is needed, patients with intermediate ELN-risk AML do no seem to benefit from SCT in CR1 as compared to standard chemotherapy. Download : Download high-res image (84KB) Download : Download full-size image Disclosures De Botton: Servier: Honoraria; Pfizer: Honoraria; Novartis: Honoraria; Celgene: Honoraria; Agios: Honoraria, Research Funding. Socie: Alexion Pharmaceuticals, Inc.: Consultancy." @default.
• W3136132014 created "2021-03-29" @default.
• W3136132014 creator A5000436961 @default.
• W3136132014 creator A5001596576 @default.
• W3136132014 creator A5010517016 @default.
• W3136132014 creator A5014705544 @default.
• W3136132014 creator A5017435311 @default.
• W3136132014 creator A5018416096 @default.
• W3136132014 creator A5023091403 @default.
• W3136132014 creator A5025277209 @default.
• W3136132014 creator A5028365885 @default.
• W3136132014 creator A5033731496 @default.
• W3136132014 creator A5036535488 @default.
• W3136132014 creator A5050799774 @default.
• W3136132014 creator A5050987906 @default.
• W3136132014 creator A5054745373 @default.
• W3136132014 creator A5057397461 @default.
• W3136132014 creator A5063101969 @default.
• W3136132014 creator A5064103067 @default.
• W3136132014 creator A5072027146 @default.
• W3136132014 creator A5072721892 @default.
• W3136132014 creator A5073263225 @default.
• W3136132014 creator A5076973611 @default.
• W3136132014 creator A5080661528 @default.
• W3136132014 creator A5081514634 @default.
• W3136132014 creator A5081527133 @default.
• W3136132014 creator A5086300417 @default.
• W3136132014 date "2017-12-07" @default.
• W3136132014 modified "2023-10-17" @default.
• W3136132014 title "Role of Allogeneic Reduced Intensity Conditioning Stem Cell Transplantation (RIC-SCT) in Older Patients with Acute Myeloid Leukemia (AML): Analysis of the ALFA-1200 Study" @default.
• W3136132014 doi "https://doi.org/10.1182/blood.v130.suppl_1.466.466" @default.
• W3136132014 hasPublicationYear "2017" @default.
• W3136132014 type Work @default.
• W3136132014 sameAs 3136132014 @default.
• W3136132014 citedByCount "0" @default.
• W3136132014 crossrefType "journal-article" @default.
• W3136132014 hasAuthorship W3136132014A5000436961 @default.
• W3136132014 hasAuthorship W3136132014A5001596576 @default.
• W3136132014 hasAuthorship W3136132014A5010517016 @default.
• W3136132014 hasAuthorship W3136132014A5014705544 @default.
• W3136132014 hasAuthorship W3136132014A5017435311 @default.
• W3136132014 hasAuthorship W3136132014A5018416096 @default.
• W3136132014 hasAuthorship W3136132014A5023091403 @default.
• W3136132014 hasAuthorship W3136132014A5025277209 @default.
• W3136132014 hasAuthorship W3136132014A5028365885 @default.
• W3136132014 hasAuthorship W3136132014A5033731496 @default.
• W3136132014 hasAuthorship W3136132014A5036535488 @default.
• W3136132014 hasAuthorship W3136132014A5050799774 @default.
• W3136132014 hasAuthorship W3136132014A5050987906 @default.
• W3136132014 hasAuthorship W3136132014A5054745373 @default.
• W3136132014 hasAuthorship W3136132014A5057397461 @default.
• W3136132014 hasAuthorship W3136132014A5063101969 @default.
• W3136132014 hasAuthorship W3136132014A5064103067 @default.
• W3136132014 hasAuthorship W3136132014A5072027146 @default.
• W3136132014 hasAuthorship W3136132014A5072721892 @default.
• W3136132014 hasAuthorship W3136132014A5073263225 @default.
• W3136132014 hasAuthorship W3136132014A5076973611 @default.
• W3136132014 hasAuthorship W3136132014A5080661528 @default.
• W3136132014 hasAuthorship W3136132014A5081514634 @default.
• W3136132014 hasAuthorship W3136132014A5081527133 @default.
• W3136132014 hasAuthorship W3136132014A5086300417 @default.
• W3136132014 hasConcept C126322002 @default.
• W3136132014 hasConcept C141071460 @default.
• W3136132014 hasConcept C143998085 @default.
• W3136132014 hasConcept C197934379 @default.
• W3136132014 hasConcept C2776694085 @default.
• W3136132014 hasConcept C2776755627 @default.
• W3136132014 hasConcept C2778041864 @default.
• W3136132014 hasConcept C2778336483 @default.
• W3136132014 hasConcept C2778729363 @default.
• W3136132014 hasConcept C2779117419 @default.
• W3136132014 hasConcept C2779263901 @default.
• W3136132014 hasConcept C2911091166 @default.
• W3136132014 hasConcept C71924100 @default.
• W3136132014 hasConcept C90924648 @default.
• W3136132014 hasConceptScore W3136132014C126322002 @default.
• W3136132014 hasConceptScore W3136132014C141071460 @default.
• W3136132014 hasConceptScore W3136132014C143998085 @default.
• W3136132014 hasConceptScore W3136132014C197934379 @default.
• W3136132014 hasConceptScore W3136132014C2776694085 @default.
• W3136132014 hasConceptScore W3136132014C2776755627 @default.
• W3136132014 hasConceptScore W3136132014C2778041864 @default.
• W3136132014 hasConceptScore W3136132014C2778336483 @default.
• W3136132014 hasConceptScore W3136132014C2778729363 @default.
• W3136132014 hasConceptScore W3136132014C2779117419 @default.
• W3136132014 hasConceptScore W3136132014C2779263901 @default.
• W3136132014 hasConceptScore W3136132014C2911091166 @default.
• W3136132014 hasConceptScore W3136132014C71924100 @default.
• W3136132014 hasConceptScore W3136132014C90924648 @default.
• W3136132014 hasLocation W31361320141 @default.
• W3136132014 hasOpenAccess W3136132014 @default.
• W3136132014 hasPrimaryLocation W31361320141 @default.
• W3136132014 hasRelatedWork W154474755 @default.
• W3136132014 hasRelatedWork W2241382955 @default.
• W3136132014 hasRelatedWork W2248002030 @default.
• W3136132014 hasRelatedWork W2505156634 @default.
• W3136132014 hasRelatedWork W2556675457 @default.
• W3136132014 hasRelatedWork W2558445882 @default.

• next